Featured Research

from universities, journals, and other organizations

Novel drug combination offers therapeutic promise for hard-to-treat cancers

Date:
September 12, 2011
Source:
Brigham and Women's Hospital
Summary:
Researchers have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments.

Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments.

These findings are published in Cancer Cell on September 13, 2011.

While numerous anti-cancer drugs are being developed, many tumors do not respond to currently available single therapies. As such, there is a major push to identify new drug combinations that can work together to treat these resistant cancers . The drug combination identified by BWH researchers was shown to successfully treat two models of aggressive cancers: a nervous system tumor associated with neurofibromatosis type 1, and KRAS-mutant lung cancer, a form of lung cancer that accounts for about 25 percent of all lung cancers.

"Without a targeted treatment that works, these two cancers are currently being treated with chemotherapy with variable success," said Dr. Karen Cichowski, Associate Professor in Genetics at BWH and lead author of the paper. "By identifying a more effective targeted treatment, the outcome and survival rate for these cancers may see a drastic improvement, and patients may avoid the typical side-effects of chemotherapy."

Researchers took the approach of combining two targeted agents, one the mTOR inhibitor rapamycin, which suppressed tumor growth, along with the HSP90 inhibitor IPI-504 from Infinity Pharmaceuticals, which triggers a specific kind of stress in cancer cells. Together, but not alone, these drugs promoted dramatic tumor regression in these two distinct cancers in mice.

"It's like hitting the tumor cell from two different angles," explains Dr. Cichowski. "Using one drug to put on the brakes and another to apply stress to an already stressed cancer cell, which ultimately triggers its self-destruction."

These studies have inspired the testing of a drug combination that is now in a Phase I clinical trial, specifically in KRAS-mutant lung cancer.

"The identification of this promising therapeutic combination sets the stage for developing other combinations and may also prove effective in other cancers through further research," said Dr. Cichowski.

The research was funded by the National Cancer Institute and the Ludwig Center at Dana-Farber/Harvard Cancer Center.


Story Source:

The above story is based on materials provided by Brigham and Women's Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Thomas De Raedt, Zandra Walton, Jessica L. Yecies, Danan Li, Yimei Chen, Clare F. Malone, Ophιlia Maertens, Seung Min Jeong, Roderick T. Bronson, Valerie Lebleu, Raghu Kalluri, Emmanuel Normant, Marcia C. Haigis, Brendan D. Manning, Kwok-Kin Wong, Kay F. Macleod, Karen Cichowski. Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors. Cancer Cell, 2011; 20 (3): 400-413 DOI: 10.1016/j.ccr.2011.08.014

Cite This Page:

Brigham and Women's Hospital. "Novel drug combination offers therapeutic promise for hard-to-treat cancers." ScienceDaily. ScienceDaily, 12 September 2011. <www.sciencedaily.com/releases/2011/09/110912153218.htm>.
Brigham and Women's Hospital. (2011, September 12). Novel drug combination offers therapeutic promise for hard-to-treat cancers. ScienceDaily. Retrieved September 29, 2014 from www.sciencedaily.com/releases/2011/09/110912153218.htm
Brigham and Women's Hospital. "Novel drug combination offers therapeutic promise for hard-to-treat cancers." ScienceDaily. www.sciencedaily.com/releases/2011/09/110912153218.htm (accessed September 29, 2014).

Share This



More Health & Medicine News

Monday, September 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How 'Yes Means Yes' Defines Sexual Assault

How 'Yes Means Yes' Defines Sexual Assault

Newsy (Sep. 29, 2014) — Aimed at reducing sexual assaults on college campuses, California has adopted a new law changing the standard of consent for sexual activity. Video provided by Newsy
Powered by NewsLook.com
Scientists May Have Found An Early Sign Of Pancreatic Cancer

Scientists May Have Found An Early Sign Of Pancreatic Cancer

Newsy (Sep. 29, 2014) — Researchers looked at 1,500 blood samples and determined people who developed pancreatic cancer had more branched chain amino acids. Video provided by Newsy
Powered by NewsLook.com
Why Is Big Tobacco Voluntarily Warning You About E-Cigs?

Why Is Big Tobacco Voluntarily Warning You About E-Cigs?

Newsy (Sep. 29, 2014) — Big tobacco companies are voluntarily printing health warnings on their e-cigarette packages — a move some are calling part of a PR strategy. Video provided by Newsy
Powered by NewsLook.com
Why Pediatricians Endorse IUDs, Implants For Teens

Why Pediatricians Endorse IUDs, Implants For Teens

Newsy (Sep. 29, 2014) — New recommendations from the American Academy of Pediatrics point to intrauterine devices and implants as good forms of birth control for teens. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins